Sophia Genetics SA is a Switzerland-based company engaged in the software publishing sector. The Company offer a cloud-based Software-as-a-Service platform - the SOPHiA DDM, which is data-driven medicine platform enabling insights from disparate, complex datasets to improve diagnosis, treatment, and drug development. The Company has offices in Switzerland, France and the United Kingdom and operates worldwide.

Employees

415

Sector

Advanced Medical Equipment & Technology

More about the company

Quotes

Date	Price	Change	Volume
16/03/26	4.860 $	+5.42%	56,878
13/03/26	4.610 $	+0.22%	94,334
12/03/26	4.600 $	+2.22%	122,571
11/03/26	4.500 $	+0.22%	133,880
10/03/26	4.490 $	+0.67%	166,010

Delayed Quote Nasdaq

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

4.610USD

Average target price

7.667USD

Spread / Average Target

+66.31%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Real-time Estimate Cboe BZX Other stock markets 17:22:16 16/03/2026 GMT			5-day change	1st Jan Change
4.870 ^USD	+5.64%		+8.97%	+4.07%

03-03	SOPHiA GENETICS SA Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-03	SOPHiA GENETICS SA, Q4 2025 Earnings Call, Mar 03, 2026

Capitalization	330M 288M 261M 249M 452M 30.5B 469M 3.1B 1.23B 14.59B 1.24B 1.21B 52.64B	P/E ratio 2026 *	-5.15x	P/E ratio 2027 *	-6.54x
Enterprise value	330M 288M 261M 249M 452M 30.5B 469M 3.1B 1.23B 14.59B 1.24B 1.21B 52.64B	EV / Sales 2026 *	3.54x	EV / Sales 2027 *	2.96x
Free-Float	78.88%	Yield 2026 *	-	Yield 2027 *	-

03-03	SOPHiA GENETICS SA Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-03	SOPHiA GENETICS SA, Q4 2025 Earnings Call, Mar 03, 2026
03-03	SOPHiA GENETICS SA Reaffirms Earnings Guidance for the Fiscal Year 2026	CI
03-03	Sophia Genetics reports fourth quarter and full year 2025 results	RE
02-10	SOPHiA Genetics Announces Major Expansion in the United States with the Signing of Two Major Integrated Health Systems	CI
01-28	Sophia Genetics Sa Announces Amendment to Credit Agreement with Additional Loan Tranches and Warrant Issuance	CI
01-12	SOPHiA GENETICS SA Announces CEO Changes	CI
01-12	Sophia Genetics Sa Appoints Kevin Puylaert as Chief Sales Officer, Effective January 2026	CI
01-12	Sophia Genetics Sa Provides Earnings Guidance for 2026	CI
01-12	SOPHiA GENETICS SA Announces Preliminary Unaudited Sales Results for Fourth Quarter and Year Ended December 31, 2025	CI
01-07	Sophia Genetics and MD Anderson announce collaboration to accelerate AI-driven precision oncology	RE
01-07	SOPHiA GENETICS and The University of Texas MD Anderson Cancer Center Announce Strategic Collaboration to Accelerate AI-Driven Precision Oncology	CI
12-23	Swiss stocks - Factors to watch on December 23	RE

07/08/24	Morgan Stanley Downgrades SOPHiA GENETICS to Equal Weight From Overweight, Adjusts Price Target to $5 From $10	MT
06/08/24	Top Midday Decliners	MT
27/06/24	Guggenheim Initiates SOPHiA GENETICS at Buy With $6 Price Target	MT
29/11/23	RBC Initiates SOPHiA GENETICS at Outperform With $8 Price Target, Notes 'Attractive' Entry Point, Exposure to Long-Term Growth in Sequencing, Life Science Research	MT
10/05/23	Credit Suisse Raises SOPHiA GENETICS' Price Target to $5 From $2.25 After 'Solid' Q1 Results, Keeps Neutral Rating	MT

SOPHiA GENETICS SA Share Price

Equities

SOPH

CH1125843347

Advanced Medical Equipment & Technology

Valuation: SOPHiA GENETICS SA

Chart: SOPHiA GENETICS SA

Latest news: SOPHiA GENETICS SA

Last Transcript: SOPHiA GENETICS SA

Analysts' recommendations: SOPHiA GENETICS SA

Press Releases: SOPHiA GENETICS SA

News in other languages: SOPHiA GENETICS SA

Quotes and Performance

Course Extremes

Managers and Directors: SOPHiA GENETICS SA

Medical Software & Technology Services

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

03-03	SOPHiA GENETICS Reports Fourth Quarter and Full Year 2025 Results	PR
02-25	SOPHiA GENETICS to Present at the 46th Annual TD Cowen Health Care Conference	PR
02-17	SOPHiA GENETICS to Announce Financial Results for Fourth Quarter and Full Year 2025 on March 3, 2026	PR
02-10	SOPHiA GENETICS Announces Major Expansion in the United States with the Signing of Two Major Integrated Health Systems	PR
02-10	SOPHiA GENETICS : AZ Delta Roeselare Joins the SOPHiA GENETICS Community	PU

25/06/24	SOPHiA GENETICS : Of SOPHiA GENETICS SA Form 6 K
15/02/24	Un triumvirat à la tête de Swisscom Ventures
20/11/23	Las mejores acciones para ganar en bolsa en Wall Street en 2024
13/02/23	AstraZeneca : partenariat renforcé avec Sophia Genetics
14/12/21	Les sociétés suisses ont préféré l'étranger pour entrer en Bourse

1 day	+5.64%
1 week	+8.97%
Current month	+8.00%
1 month	+2.32%
3 months	+1.04%
6 months	+50.46%
Current year	+4.07%

1 week	4.33	4.87
1 month	4	5.02
Current year	4	5.7
1 year	2.58	5.7
3 years	2.13	7.37
5 years	1.68	19.8
10 years	1.68	19.8

Manager	Title	Age	Since
Jurgi Camblong CEO	Chief Executive Officer	47	31/12/2010
George Cardoza DFI	Director of Finance/CFO	64	04/11/2024
Ross Muken PSD	President	46	04/11/2024

Director	Title	Age	Since
Jurgi Camblong BRD	Director/Board Member	47	28/02/2011
Vincent Ossipow BRD	Director/Board Member	57	31/05/2014
Troy Cox CHM	Chairman	61	31/01/2020

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
SOPHIA GENETICS SA	+5.64%	+8.97%	+51.88%	-11.48%	330M
VEEVA SYSTEMS INC.	+3.73%	-5.42%	-21.94%	+5.23%	29.4B
PRO MEDICUS LIMITED	-1.02%	-0.79%	-43.76%	+111.59%	9.73B
SECTRA AB	+0.34%	+9.50%	-6.67%	+48.75%	4.74B
QINGSONG HEALTH CORPORATION	-9.59%	+34.91%	-	-	3.41B
HEARTFLOW, INC.	+2.76%	-8.89%	-	-	1.74B
GENERATE BIOMEDICINES, INC.	-5.50%	+0.33%	-	-	1.67B
OMNICELL, INC.	+0.89%	-13.07%	+4.23%	-39.22%	1.56B
XUNFEI HEALTHCARE TECHNOLOGY CO., LTD.	+0.20%	-4.92%	-48.78%	-	1.16B
B-SOFT CO.,LTD.	+1.41%	-0.59%	-31.94%	-48.05%	1.12B
Average	-0.10%	+3.86%	-13.86%	+11.14%	5.49B
Weighted average by Cap.	+1.25%	-1.06%	-24.38%	+28.83%

	2026 *	2027 *
Net sales	93.25M 81.22M 73.54M 70.16M 128M 8.61B 132M 874M 347M 4.12B 350M 343M 14.86B	112M 97.12M 87.93M 83.89M 153M 10.29B 158M 1.04B 415M 4.92B 418M 410M 17.76B
Net income	-61.77M -53.8M -48.71M -46.47M -84.54M -5.7B -87.65M -579M -230M -2.73B -232M -227M -9.84B	-49.41M -43.04M -38.97M -37.18M -67.63M -4.56B -70.12M -463M -184M -2.18B -185M -182M -7.87B
Net Debt	-	-